Inspire Medical Systems (INSP) vs NovoCure (NVCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NovoCure (NVCR) has outperformed Inspire Medical Systems (INSP) over the past year, losing 0.9% versus a loss of 15.1%. Over five years, INSP leads with a -72.8% price change compared with -87.3% for NVCR. Inspire Medical Systems is the larger company by market cap ($1.93 billion vs $1.66 billion), about 1.2 times the size.
Inspire Medical Systems converts more of its revenue into profit, with a net margin of 15.9% versus -20.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INSP | NVCR |
|---|---|---|
| Share price | $66.69 | $14.22 |
| Market cap | $1.93B | $1.66B |
| 1-day change | -1.13% | -3.00% |
| YTD return | -27.69% | +9.98% |
| 1-year return | -15.09% | -0.91% |
| 5-year return | -72.80% | -87.33% |
| P/E ratio (TTM) | 14.69 | — |
| Forward P/E | 43.16 | — |
| EPS (TTM) | $4.54 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $911.98M | $655.35M |
| Revenue growth (YoY) | +13.60% | +8.28% |
| Net income (latest FY) | $145.42M | $-136.23M |
| Gross margin | 85.39% | 74.54% |
| Operating margin | 5.59% | -23.47% |
| Net margin | 15.95% | -20.79% |
| 52-week high | $147.03 | $21.45 |
| 52-week low | $38.91 | $9.82 |
| Distance from 52-week high | -54.64% | -33.71% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -2.53% | +88.89% |
| Average volume | 798.17K | 1.45M |
| Shares outstanding | 28.91M | 116.45M |
| Employees | 1,333 | 1,605 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCR has outperformed INSP by 14.2 percentage points over the past year.
- Inspire Medical Systems is more profitable, keeping 15.9 cents of every revenue dollar as net income versus -20.8 cents for NovoCure.
- Inspire Medical Systems grew revenue faster in its latest fiscal year (+13.60% vs +8.28%).
About Inspire Medical Systems
INSP stock →Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA.
Health Care · Medical/Dental Instruments · 1,333 employees
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
INSP vs NVCR FAQ
Which is bigger, Inspire Medical Systems or NovoCure?
Inspire Medical Systems (INSP) is larger, with a market capitalization of $1.93B compared with $1.66B for NovoCure (NVCR).
Which stock has performed better over the past year, INSP or NVCR?
NVCR returned -0.91% over the past 12 months, compared with -15.09% for INSP (price return, excluding dividends). Past performance does not predict future results.
Are Inspire Medical Systems and NovoCure in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.